One-time gene edit slashes bad cholesterol for over a year
A four-person pilot study, published in The New England Journal of Medicine, found that a single liver-targeted CRISPR-Cas9 therapy reducing ANGPTL3 activity lowered LDL cholesterol by about 50% and triglycerides by about 55% in the highest-dose group, with these effects persisting for more than a year. Side effects were generally mild, though one participant with extensive cardiovascular disease died, and larger trials are needed to confirm long-term safety and efficacy.